FDA approves Novo Nordisk’s Saxenda for adolescent obesity
December 7, 2020Sales and Marketing FDA, Novo Nordisk, saxenda
The FDA has awarded US approval to Novo Nordisk’s Saxenda (liraglutide) 3mg injection to treat obesity in patients between the …
Top Ten most popular articles on Pharmafile.com this week
December 4, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, Dupixent, EMA, UK, Vaccine, top ten
As the year winds to a close, excitement is rising around the efficacy and availability of COVID-19 vaccines around the …
New research links metformin to decreased mortality risk in female patients hospitalised with COVID-19
December 4, 2020Medical Communications, Research and Development COVID-19, Vaccine, metformin
Researchers from the University of Minnesota Medical School (UMMS) and UnitedHealth Group have uncovered potential benefit of metformin, a generic …
IBM uncovers “precision phishing campaign” targeting global COVID-19 vaccine cold chain supply
December 4, 2020Manufacturing and Production, Medical Communications, Research and Development COVID-19, Vaccine, ibm
US tech firm IBM has reported that it has identified attempts by unknown parties to hack and disrupt elements of …
FDA approves BioCryst’s Orladeyo for reducing hereditary angioedema attacks
December 4, 2020Medical Communications, Sales and Marketing BioCryst, FDA, Orladeyo
BioCryst has scored FDA for its therapy Orladeyo (berotralstat) for reducing or preventing hereditary angioedema (HAE) attacks in patients over …
MSD cashes in on Moderna investment as FDA mulls COVID-19 vaccine approval
December 4, 2020Medical Communications, Sales and Marketing MSD, Moderna
Moderna has wrestled its way to the forefront of the industry amidst the COVID-19 pandemic, becoming one of its most …
Jazz and PharmaMar’s Zepzelca combo misses main goal in small cell lung cancer sub-population
December 3, 2020Research and Development PharmaMar, jazz pharma, trial failure
Jazz Pharma and PharmaMar have revealed that their jointly-developed therapy Zepzelca (lurbinectedin), when combined with doxorubicin, fell short of its …
Neurogene secures EMA orphan designation for gene therapy in rare, inherited aspartylglucosaminuria
December 3, 2020Sales and Marketing EMA, Neurogene, aspartylglucosaminuria
The European Medicines Agency (EMA) has bestowed Orphan Drug Designation (ODD) to Neurogene’s adeno-associated virus vector (AAV) gene therapy in …
Janssen scoops up rights to Hemera’s gene therapy for retinal geographic atrophy
December 3, 2020Sales and Marketing Hemera Biosciences, Janssen, Retina, geographic atrophy
Janssen is set to acquire the rights to Hemera Biosciences’ intravitreal gene therapy injection HMR59, the company has announced, to …
Drug-free nasal spray could prevent COVID-19 infection, promising data show
December 3, 2020Research and Development COVID-19, Nasal Spray, auris medical
Auris Medical has revealed promising new in vitro data for AM-301, its drug-free nasal spray, showing that the product could …
Roche secures emergency FDA approval for COVID-19 antibody test
December 3, 2020Sales and Marketing COVID-19, FDA, Roche
The FDA has awarded Emergency Use Authorization to Roche’s COVID-19 test to allow users in the US to analyse the …
Pharmafile.com’s weekly COVID-19 news round-up
December 2, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, Image credit: CDC, Top 5, Vaccine
EMA receives Pfizer and BioNTech’s filing for conditional approval of COVID-19 vaccine in Europe – Published on 01/12/20
FDA greenlights Gavreto for advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer in over-12s
December 2, 2020Research and Development, Sales and Marketing FDA, Gavreto, Roche
The FDA has awarded accelerated approval to Roche and Blueprint Medicines’ Gavreto (pralsetinib) for the treatment of advanced or metastatic …
European approval for Janssen’s Tremfya in active psoriatic arthritis, either alone or in combo
December 2, 2020Research and Development, Sales and Marketing Europe, Janssen, Tremfya
The European Commission has authorised Janssen’s interleukin (IL)-23 inhibitor Tremfya (guselkumab) in the treatment of active psoriatic arthritis (PsA), either …
Ovid’s Angelman syndrome therapy falls short at Phase 3
December 2, 2020Research and Development Angelman syndrome, Ovid
Ovid Therapeutics has revealed disappointing results for its therapy OV101 (gaboxadol) in the treatment of Angelman syndrome, admitting that it failed …
UK becomes first nation to approve Pfizer and BioNTech’s COVID-19 vaccine
December 2, 2020Research and Development, Sales and Marketing COVID-19, Pfizer, UK, Vaccine
The UK has become the first country worldwide to authorise Pfizer and BioNTech’s promising COVID-19 vaccine, the UK Government has …
The Autumn 2020 edition of Pharmafile is available to read for free online now!
December 1, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing infectious diseases, pharmafile, rare disease, respiratory
The Autumn 2020 edition of Pharmafile is available to read for free online now! 2020 has seen almost unprecedented disruption …
Eisai and Wren Therapeutics join forces to tackle neurodegenerative synucleinopathies
December 1, 2020Manufacturing and Production, Research and Development, Sales and Marketing Eisai, Wren Therapeutics
Eisai has forged an exclusive research partnership with Wren Therapeutics to develop new approaches in tackling neurodegenerative diseases known as …
EMA receives Pfizer and BioNTech’s filing for conditional approval of COVID-19 vaccine in Europe
December 1, 2020Manufacturing and Production, Sales and Marketing BioNTech, COVID-19, EMA, Pfizer, Vaccine
Pfizer and BioNTech have officially submitted their application to secure conditional marketing authorisation to the European Medicines Agency (EMA) for …
Grünenthal buys European rights to AstraZeneca’s Crestor for a potential $350m
December 1, 2020Manufacturing and Production, Sales and Marketing AstraZeneca, Crestor, Grunenthal
Grünenthal has picked up AstraZeneca’s statin therapy Crestor (rosuvastatin), currently approved in dyslipidaemia and hypercholesterolaemia treatment, in a deal worth …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
